Oxford Biotherapeutics
Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m
December 12, 2018Research and Development Cancer, Oxford Biotherapeutics, WuXi Biologics, alliance, deal, oncology
Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in …
Oxford BioTherapeutics hires chairman
June 27, 2013Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics, morton
Biotech firm Oxford BioTherapeutics has appointed Bryan Morton to be the company’s new non-executive chairman. Morton has over 30 years’ …
Oxford BioTherapeutics appoints new chief operations officer
May 3, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics
Oxford BioTherapeutics (OBT) has appointed Dr Esteban Pombo-Villar as its new chief operations officer (COO). In this position he will …
Oxford BioTherapeutics appoints C. Glenn Begley as a senior clinical advisor
January 17, 2012Business Services, Research and Development, Sales and Marketing C. Glenn Begley, Oxford Biotherapeutics
Oxford BioTherapeutics has appointed C. Glenn Begley as a senior clinical advisor and non-executive director of the firm. Dr Begley, …
Sanofi buys into cancer antibody research
January 26, 2011Research and Development Cancer, Oxford Biotherapeutics, Sanofi, Sanofi-Aventis, antibody drug conjugate, cancer research
Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …
Michael Moore, chairman, Oxford BioTherapeutics
January 11, 2010Research and Development Oxford Biotherapeutics, Piramed, appointment, research and development
Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman. He joins the company following five years spent at UK …
Oxford BioTherapeutics appoints Dr Jim Cornett, Dr Jon Terrett and Dr Mike Gresser
December 2, 2009Research and Development Oxford Biotherapeutics, appointment, research and development
Oxford BioTherapeutics has expanded its US operations, recruiting a number of senior industry leaders.Dr Jim Cornett will head up operations …
GSK signs oncology deal with UK biotech
May 18, 2009Research and Development, Sales and Marketing GSK, Oxford Biotherapeutics
GSK has struck a deal with Oxford BioTherapeutics to develop therapies for primary, metastatic and recurring forms of cancer. The …
Latest content
FibroFind appoints Lee Borthwick as CEO
